Earnings call transcript: Cal-Maine Foods Q1 2026 loss widens as egg prices slump

Cal-Maine Foods reported a fiscal Q1 2027 loss of $1.26 per share versus a $0.47 consensus loss, while revenue fell 41.5% year over year to $539.6 million, missing expectations by $48.2 million. Net income swung to a $58.6 million loss from a $199.3 million profit, as gross profit collapsed to $0.4 million from $311.3 million amid conventional egg oversupply, lower pricing, and higher delivery and feed costs. Shares fell 3.53% premarket to $66.13, although management highlighted $767.6 million of cash, ongoing buybacks, and plans to expand prepared-food capacity by more than 60% by the first half of fiscal 2028.

Analysis

CALM is entering the most dangerous part of a commodity trough: lower realized pricing is coinciding with rising feed and logistics costs, creating negative operating leverage that consensus may still be underestimating for the next one to two quarters. The key incremental datapoint is not retail demand but weekly layer-flock, hatch, and inventory data; until production cuts translate into fewer saleable cases, demand growth merely limits the duration of oversupply rather than restoring margins.

The strategic mix shift deserves a lower cyclicality multiple only after it proves incremental returns. Prepared foods appears profitable at the segment level, but commissioning expense, commercial ramp, and fixed-cost absorption make the next two quarters a likely earnings air pocket; capacity growth without contracted customer volumes can dilute returns and consume cash. Specialty is also less insulated than the headline mix suggests because its pricing and volumes remain linked to conventional egg economics.

The contrarian setup is that CALM's balance sheet and repurchase authorization limit solvency risk precisely when smaller producers face margin pressure. A modest flock disruption or faster-than-expected industry exits could move egg pricing sharply because supply elasticity is low; this makes an outright short unattractive near trough valuation. The market is likely underpricing both tails: another weak quarter from cost inflation versus a rapid supply-driven recovery that would make current earnings irrelevant.

Near term, expect estimate cuts and multiple pressure until Q2 demonstrates that higher feed costs are being recovered in contract pricing and prepared-foods startup costs are moderating. Over 6-18 months, the investable thesis depends on prepared-foods utilization and whether capital deployment remains disciplined rather than expanding conventional capacity into a saturated market.

Key Decisions for Investors

• Do not initiate an outright CALM short at current levels; downside from a weak Q2 is likely limited by net cash, buyback capacity, and asymmetric HPAI/supply-rationalization upside. Reassess a short only on a rally above $80 without a sustained improvement in wholesale egg pricing.
• Establish a staged long CALM position only if shares hold the $63.50 prior low and weekly industry inventory/hatch data continue declining for 4-6 weeks. Target a 20-30% recovery over 6-12 months on normalization; exit if conventional segment losses widen despite improving benchmark egg prices, signaling cost or execution deterioration.
• For a lower-beta relative-value expression, consider long CALM / short VITL in equal dollar amounts after confirmation of supply tightening. CALM has greater earnings torque to a commodity rebound, while VITL's premium valuation is more exposed if specialty-category growth normalizes; close the pair if specialty margins at CALM fall below mid-single digits for two consecutive quarters.
• Set Q2 watch triggers: conventional price realization versus benchmark, feed-cost recovery lag, prepared-foods EBIT direction, and repurchase pace. A material acceleration in buybacks alongside stable cash would validate management's valuation signal; reduced repurchases or incremental acquisition spending before prepared-foods utilization improves would weaken the downside-floor thesis.